Comparison of Biological Characteristics of Human Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells from Extremely Preterm and Term Infants

다국어 초록 (Multilingual Abstract)

BACKGROUND: Despite the progress in perinatal-neonatal medicine, complications of extremely preterm infants continue to constitute the major adverse outcomes in neonatal intensive care unit. Human umbilical cord Wharton’s Jellyderived mesenchymal stem cells (HUMSCs) may offer new hope for the treatment of intractable neonatal disorders. This study will explore the functional differences of HUMSCs between extremely preterm and term infants.
METHODS: UMSCs from 5 extremely preterm infants(weeks of gestation: 22?5 w,24?4 w,25?3 w,26 w,28 w) and 2 term infants(39 w,39?2 w) were isolated, and mesenchymal markers, pluripotent genes, proliferation rate were analyzed.
HUVECs were injured by treated with LPS and repaired by co-cultured with HUMSCs of different gestational ages.
RESULTS: All HUMSCs showed fibroblast-like adherence to plastic and positively expressed surface marker of CD105,CD73 and CD90, but did not expressed CD45,CD34,CD14,CD79a and HLA-DR; HUMSCs in extremely preterm exhibited significant increase in proliferation as evidenced by CCK8, pluripotency markers OCT-4 tested by RT-PCR also showed increase. Above all, in LPS induced co-cultured inflame systerm, HUMSCs in extremely preterm were more capable to promote wound healing and tube formation in HUVEC cultures, they promoted TGFb1 expression and inhibited IL6 expression.
CONCLUSIONS: Our results suggest that HUMSCs from extremely preterm infants may be more suitable as candidates in cell therapy for the preterm infants.

참고문헌 (Reference)

• 1 Ahn SY, "Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia" 185 : 49-54, 2017
• 2 Kumar P, "The mesenchymal stem cell secretome : A new paradigm towards cell-free therapeutic mode in regenerative medicine" 46 : 1-9, 2019
• 3 Prockop DJ, "The exciting prospects of new therapies with mesenchymal stromal cells" 19 : 1-8, 2017
• 4 Zhang Y, "The TGF-b1 induces the endothelial-to-mesenchymal transition via the UCA1/miR-455/ZEB1 regulatory axis in human umbilical vein endothelial cells" 39 : 1264-1273, 2020
• 5 Li J, "Term vs. preterm cord blood cells for the prevention of preterm brain injury" 82 : 1030-1038, 2017
• 6 Chen Y, "Stem cell-released microvesicles and exosomes as novel biomarkers and treatments of diseases" 2016 : 2417268-, 2016
• 7 Nitkin CR, "Stem cell therapy for preventing neonatal diseases in the 21st century : Current understanding and challenges" 87 : 265-276, 2020
• 8 장윤실 ; 박원순 ; 안소윤 ; 성세인, "Stem Cell Therapy for Neonatal Disorders: Prospects and Challenges" 연세대학교의과대학 58 (58): 266-271, 2017
• 9 Powell SB, "Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants" 210 : 209-213, 2019
• 10 Bhandari A, "Pulmonary outcomes in bronchopulmonary dysplasia" 30 : 219-226, 2006
• 11 Herrmann JL, "Proinflammatory stem cell signaling in cardiac ischemia" 11 : 1883-1896, 2009
• 12 Ahn SY, "Pivotal role of brain-derived neurotrophic factor secreted by mesenchymal stem cells in severe intraventricular hemorrhage in newborn rats" 26 : 145-156, 2017
• 13 Vohr BR, "Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National institute of child health and human development neonatal research network 1993–1994" 105 : 1216-1226, 2000
• 14 Bland RD, "Neonatal chronic lung disease in the post-surfactant era" 88 : 181-191, 2005
• 15 Dominici M, "Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement" 8 : 315-317, 2006
• 16 Keating A, "Mesenchymal stromal cells : new directions" 10 : 709-716, 2012
• 17 Chang YS, "Mesenchymal stem cells for bronchopulmonary dysplasia : phase 1 dose-escalation clinical trial" 164 : 966-972, 2014
• 18 Ahn SY, "Mesenchymal stem cell therapy for intractable neonatal disorders" 62 : S16-S21, 2021
• 19 Vizoso FJ, "Mesenchymal stem cell secretome : toward cell-free therapeutic strategies in regenerative medicine" 18 : 1852-, 2017
• 20 Goetz MJ, "MSC based therapies to prevent or treat bpd-a narrative review on advances and ongoing challenges" 22 : 1138-, 2021
• 21 Ciubotariu R, "Impact of delayed umbilical cord clamping on public cord blood donations: can we help future patients and benefit infant donors?" 58 : 1427-1433, 2018
• 22 Johnston MV, "Hypoxic and ischemic disorders of infants and children. Lecture for 38th meeting of Japanese Society of Child Neurology, Tokyo, Japan, July 1996" 19 : 235-239, 1997
• 23 Ko HR, "Human UCB-MSCs treatment upon intraventricular hemorrhage contributes to attenuate hippocampal neuron loss and circuit damage through BDNF-CREB signaling" 9 : 326-, 2018
• 24 Cotten CM, "Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy" 164 : 973-979, 2014
• 25 Cotten CM, "Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy" 164 : 973-979, 2014
• 26 Garzon I, "Expanded differentiation capability of human wharton’s jelly stem cells toward pluripotency : a systematic review" 26 : 301-312, 2020
• 27 Muehlbacher T, "Evidence for the management of bronchopulmonary dysplasia in very preterm infants" 8 : 298-, 2021
• 28 Sweet DG, "European consensus guidelines on the management of respiratory distress syndrome–2019 update" 115 : 432-450, 2019
• 29 Li Z, "Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation" 6 : e20526-, 2011
• 30 Huang P, "Differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells into germ-like cells in vitro" 109 : 747-754, 2010
• 31 Gendaszewska-Darmach E, "Degradation of extracellular nucleotides and their analogs in HeLa and HUVEC cell cultures" 50 : 973-984, 2003
• 32 Chang YS, "Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lunginjury" 51 : 391-399, 2014
• 33 Davies JE, "Concise review : Wharton’s Jelly : the rich, but enigmatic, source of mesenchymal stromal cells" 6 : 1620-1630, 2017
• 34 Squillaro T, "Clinical trials with mesenchymal stem cells : an update" 25 : 829-848, 2016
• 35 Aslam M, "Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease" 180 : 1122-1130, 2009
• 36 Malhotra A, "Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants : protocol for a safety and feasibility study" 10 : e036065-, 2020
• 37 Tsuji M, "Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy : a pilot study for feasibility and safety" 10 : 4603-, 2020
• 38 Duscher D, "Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells" 4 : 7144-, 2014